Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 40
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MFG-E8 (LACTADHERIN), a novel marker associated with cerebral amyloid angiopathy

  • Marazuela, Paula|||0000-0003-1038-5242
  • Solé Piñol, Montserrat|||0000-0003-4240-6562
  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Camacho, Jessica|||0000-0001-8018-8274
  • Martinez-Saez, Elena|||0000-0001-6004-5364
  • Kuiperij, H. Bea
  • Verbeek, Marcel M.
  • De Kort, Anna M.|||0000-0002-5679-516X
  • Schreuder, Floris H. B. M.
  • Klijn, Catharina J. M.
  • Castillo-Ribelles, Laura|||0000-0001-9380-7839
  • Pancorbo, Olalla|||0000-0003-3240-4862
  • Rodriguez-Luna, David|||0000-0001-8053-4536
  • Pujadas, Francesc|||0000-0003-3569-2601
  • Delgado Martínez, María Pilar|||0000-0002-1628-4488
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
  • Pizarro, Jesús
The online version contains supplementary material available at 10.1186/s40478-021-01257-9.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Ceruletide and Alpha-1 Antitrypsin as a Novel Combination Therapy for Ischemic Stroke

  • Simats, Alba
  • Ramiro Pascual, Laura
  • Valls, Raquel
  • Ramón, Helena de
  • García-Rodríguez, Paula
  • Orset, Cyrille
  • Artigas, Laura
  • Sardon, Teresa
  • Rosell, Anna
  • Montaner, Joan
Ischemic stroke is a primary cause of morbidity and mortality worldwide. Beyond the approved thrombolytic therapies, there is no effective treatment to mitigate its progression. Drug repositioning combinational therapies are becoming promising approaches to identify new uses of existing drugs to synergically target multiple disease-response mechanisms underlying complex pathologies. Here, we used a systems biology-based approach based on artificial intelligence and pattern recognition tools to generate in silico mathematical models mimicking the ischemic stroke pathology. Combinational treatments were acquired by screening these models with more than 5 million two-by-two combinations of drugs. A drug combination (CA) formed by ceruletide and alpha-1 antitrypsin showing a predicted value of neuroprotection of 92% was evaluated for their synergic neuroprotective effects in a mouse pre-clinical stroke model. The administration of both drugs in combination was safe and effective in reducing by 39.42% the infarct volume 24 h after cerebral ischemia. This neuroprotection was not observed when drugs were given individually. Importantly, potential incompatibilities of the drug combination with tPA thrombolysis were discarded in vitro and in vivo by using a mouse thromboembolic stroke model with t-PA-induced reperfusion, revealing an improvement in the forepaw strength 72 h after stroke in CA-treated mice. Finally, we identified the predicted mechanisms of action of ceruletide and alpha-1 antitrypsin and we demonstrated that CA modulates EGFR and ANGPT-1 levels in circulation within the acute phase after stroke. In conclusion, we have identified a promising combinational treatment with neuroprotective effects for the treatment of ischemic stroke., Neurovascular Research Laboratory acknowledges funding for this project by PI15/00354 and PI18/00804 grants from Instituto Carlos III; the Spanish neurovascular research network INVICTUS PLUS (RD16/0019/0021) also from the Instituto de Salud Carlos III (co-financed by the European Regional Development Fund, FEDER); the program 2017-SGR-1427 from the Generalitat de Catalunya; and the “Advanced Neuroprotection Repurposing Drugs and Nutraceuticals for Stroke in Andalusia: NARDNIA Project,” and COMBINA2 project both funded by the Andalusian Ministry of Health (PE-0527–2019 and PY20-01351). L.R. is supported by a predoctoral fellowship grant (IFI17/00012), from Instituto de Salud Carlos III., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Functional Recovery and Serum Angiogenin Changes According to Intensity of Rehabilitation Therapy After Stroke

  • Garcia Rodriguez, Nicolas
  • Rodriguez Gonzalez, Susana
  • Ignacio Tejada, Pedro
  • Miranda-Artieda, Zuberoa Maite
  • Ridao, Natalia
  • Buxo Masip, Xavier
  • Perez Bazan, Laura Mónica
  • Quintana Luque, Manuel
  • Olive Gadea, Marta
  • Penalba Morenilla, Anna
  • Rosell Novel, Anna
  • Inzitari, Marco
  • Perez-Mesquida, Maria Engracia
Angiogenina; Terapia intensiva; Rehabilitación, Angiogenin; Intensive therapy; Rehabilitation, Angiogenina; Teràpia intensiva; Rehabilitació, Background: Rehabilitation is still the only treatment available to improve functional status after the acute phase of stroke. Most clinical guidelines highlight the need to design rehabilitation treatments considering starting time, intensity, and frequency, according to the tolerance of the patient. However, there are no homogeneous protocols and the biological effects are under investigation. Objective: To investigate the impact of rehabilitation intensity (hours) after stroke on functional improvement and serum angiogenin (ANG) in a 6-month follow-up study. Methods: A prospective, observational, longitudinal, and multicenter study with three cohorts: strokes in intensive rehabilitation therapy (IRT, minimum 15 h/week) vs. conventional therapy (NO-IRT, <15 h/week), and controls subjects (without known neurological, malignant, or inflammatory diseases). A total of seven centers participated, with functional evaluations and blood sampling during follow-up. The final cohort includes 62 strokes and 43 controls with demographic, clinical, blood samples, and exhaustive functional monitoring. Results: The median (IQR) number of weekly hours of therapy was different: IRT 15 (15–16) vs. NO-IRT 7.5 (5–9), p < 0.01, with progressive and significant improvements in both groups. However, IRT patients showed earlier improvements (within 1 month) on several scales (CAHAI, FMA, and FAC; p < 0.001) and the earliest community ambulation achievements (0.89 m/s at 3 months). There was a significant difference in ANG temporal profile between the IRT and NO-IRT groups (p < 0.01). Additionally, ANG was elevated at 1 month only in the IRT group (p < 0.05) whereas it decreased in the NO-IRT group (p < 0.05). Conclusions: Our results suggest an association of rehabilitation intensity with early functional improvements, and connect the rehabilitation process with blood biomarkers., NG-R holds a VHIR fellowship and MO-G a Joan Margarit VHIR fellowship. Research grants: from the Instituto de Salud Carlos III and European Regional Development Funds (PI16/00981, PI19/00186, RD16/0019/0021, and RD16/0019/0008), 2017-SGR-1427 program from the Generalitat de Catalunya-AGAUR, and Clinical Translational Program for Regenerative Medicine in Catalonia (P-CMR [C]).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Angiogenin in the Neurogenic Subventricular Zone After Stroke

  • Gabriel Salazar, Marina
  • Lei (Santiago), Ting
  • Grayston Morales, Alba
  • Costa Riu, Carme
  • Medina Gutierrez, Esperanza
  • Montaner Villalonga, Joan
  • Rosell Novel, Anna
  • Comabella Lopez, Manuel
Angiogenina; Exercici; Neuroreparació, Angiogenina; Ejercicio; Neuroreparación, Angiogenin; Exercise; Neurorepair, Ischemic stroke is a leading cause of death and disability worldwide with effective acute thrombolytic treatments. However, brain repair mechanisms related to spontaneous or rehabilitation-induced recovery are still under investigation, and little is known about the molecules involved. The present study examines the potential role of angiogenin (ANG), a known regulator of cell function and metabolism linked to neurological disorders, focusing in the neurogenic subventricular zone (SVZ). Angiogenin expression was examined in the mouse SVZ and in SVZ-derived neural stem cells (NSCs), which were exposed to exogenous ANG treatment during neurosphere formation as well as in other neuron-like cells (SH-SY5Y). Additionally, male C57Bl/6 mice underwent a distal permanent occlusion of the middle cerebral artery to study endogenous and exercise-induced expression of SVZ-ANG and neuroblast migration. Our results show that SVZ areas are rich in ANG, primarily expressed in DCX+ neuroblasts but not in nestin+NSCs. In vitro, treatment with ANG increased the number of SVZ-derived NSCs forming neurospheres but could not modify SH-SY5Y neurite differentiation. Finally, physical exercise rapidly increased the amount of endogenous ANG in the ipsilateral SVZ niche after ischemia, where DCX-migrating cells increased as part of the post-stroke neurogenesis process. Our findings position for the first time ANG in the SVZ during post-stroke recovery, which could be linked to neurogenesis., MG-S was supported by a pre-doctoral fellowship from the Vall d'Hebron Research Institute, AR was supported by the Miguel Servet program and AG holds a pre-doctoral fellowship both from Instituto Carlos III (CPII15/00003 and FI17/00073, respectively), and TL was supported by the China Scholarship Council (CSC-201706170048). This research has been funded by grants PI16/00981, PI19/00186, and RD16/0019/0021 (RETICS-INVICTUS PLUS) from the Instituto de Salud Carlos III co-financed by the European Regional Development Funds, and by the Generalitat de Catalunya (2017SGR 1427).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer’s disease

  • Camacho Soriano, Jessica
  • Rábano, Alberto
  • Marazuela Fuentes, Paula
  • Bonaterra Pastra, Anna
  • Serna Alonso, Garazi
  • Moline Marimon, Teresa
  • Ramon y Cajal Agüeras, Santiago
  • Martinez Saez, Elena Antima
  • Hernandez Guillamon, Maria Mar
Alzheimer; CD2AP; Enfermedad de Pick, Alzheimer's disease; CD2AP; Pick's disease, Alzheimer; CD2AP; Malaltia de Pick, Genome-wide association studies have described several genes as genetic susceptibility loci for Alzheimer's disease (AD). Among them, CD2AP encodes CD2-associated protein, a scaffold protein implicated in dynamic actin remodeling and membrane trafficking during endocytosis and cytokinesis. Although a clear link between CD2AP defects and glomerular pathology has been described, little is known about the function of CD2AP in the brain. The aim of this study was to analyze the distribution of CD2AP in the AD brain and its potential associations with tau aggregation and β-amyloid (Aβ) deposition. First, we performed immunohistochemical analysis of CD2AP expression in brain tissue from AD patients and controls (N = 60). Our results showed granular CD2AP immunoreactivity in the human brain endothelium in all samples. In AD cases, no CD2AP was found to be associated with Aβ deposits in vessels or parenchymal plaques. CD2AP neuronal inclusions similar to neurofibrillary tangles (NFT) and neuropil thread-like deposits were found only in AD samples. Moreover, immunofluorescence analysis revealed that CD2AP colocalized with pTau. Regarding CD2AP neuronal distribution, a hierarchical progression from the entorhinal to the temporal and occipital cortex was detected. We found that CD2AP immunodetection in neurons was strongly and positively associated with Braak neurofibrillary stage, independent of age and other pathological hallmarks. To further investigate the association between pTau and CD2AP, we included samples from cases of primary tauopathies (corticobasal degeneration [CBD], progressive supranuclear palsy [PSP], and Pick's disease [PiD]) in our study. Among these cases, CD2AP positivity was only found in PiD samples as neurofibrillary tangle-like and Pick body-like deposits, whereas no neuronal CD2AP deposits were detected in PSP or CBD samples, which suggested an association of CD2AP neuronal expression with 3R-Tau-diseases. In conclusion, our findings open a new road to investigate the complex cellular mechanism underlying the tangle conformation and tau pathology in the brain., This work was funded by Instituto de Salud Carlos III (ISCIII) (PI17/00275, PI20/00465), cofinanced by the European Regional Development Fund (FEDER). The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021). M.H.-G. is supported by the Miguel Servet Programme, ISCIII, Spain (CPII17/00010)
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer’s Disease

  • Bonaterra Pastra, Anna
  • Fernández de Retana, Sofía
  • Rivas-Urbina, Andrea
  • Puig, Núria
  • Benítez, Sònia
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Pujadas Navinés, Francesc
  • Montaner Villalonga, Joan
  • Hernandez Guillamon, Maria Mar
Malaltia d'Alzheimer; Apolipoproteïnes; Angiopatia amiloide cerebral, Enfermedad de Alzheimer; Apolipoproteínas; Angiopatía amiloide cerebral, Alzheimer’s disease; Apolipoproteins; Cerebral amyloid angiopathy, Cerebral amyloid angiopathy (CAA) refers to beta-amyloid (Aβ) deposition in brain vessels and is clinically the main cause of lobar intracerebral hemorrhage (ICH). Aβ can also accumulate in brain parenchyma forming neuritic plaques in Alzheimer’s disease (AD). Our study aimed to determine whether the peripheral lipid profile and lipoprotein composition are associated with cerebral beta-amyloidosis pathology and may reflect biological differences in AD and CAA. For this purpose, lipid and apolipoproteins levels were analyzed in plasma from 51 ICH-CAA patients (collected during the chronic phase of the disease), 60 AD patients, and 60 control subjects. Lipoproteins (VLDL, LDL, and HDL) were isolated and their composition and pro/antioxidant ability were determined. We observed that alterations in the lipid profile and lipoprotein composition were remarkable in the ICH-CAA group compared to control subjects, whereas the AD group presented no specific alterations compared with controls. ICH-CAA patients presented an atheroprotective profile, which consisted of lower total and LDL cholesterol levels. Plasma from chronic ICH-CAA patients also showed a redistribution of ApoC-III from HDL to VLDL and a higher ApoE/ApoC-III ratio in HDL. Whether these alterations reflect a protective response or have a causative effect on the pathology requires further investigation., This research was funded by Instituto de Salud Carlos III (co-financed by the European Regional Development Fund FEDER “Una manera de hacer Europa”), grant numbers PI13/00364, PI16/00471, PI14/01134 and PI17/00275. A.R.-U. was funded by Instituto de Salud Carlos III predoctoral contract FI17/00031. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain [RD16/0019/0021]. J.L.S.-Q. is a member of the CIBER of Diabetes and Metabolism (CIBERDEM), ISCIII, Spain. M.H.-G. is supported by the Miguel Servet programme, ISCIII, Spain [CPII17/00010]. A.R.-U., N.P., S.B. and J.L.S.-Q. are members of the Quality Research Group 2017-SGR-1149 from Generalitat de Catalunya. A.R.-U., N.P., S.B. and J.L.S.-Q. are members of the Group of Vascular Biology from the Spanish Atherosclerosis Society.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy

  • Marazuela Fuentes, Paula
  • Solé Piñol, Montserrat
  • Bonaterra Pastra, Anna
  • Pizarro Gonzálvez, Jesús
  • Camacho Soriano, Jessica
  • Martinez Saez, Elena Antima
  • Castillo Ribelles, Laura
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Pujadas Navinés, Francesc
  • Delgado Martínez, Maria Pilar
  • Hernandez Guillamon, Maria Mar
Malaltia d'Alzheimer; Biomarcadors; Microdissecció de captura làser, Alzheimer's disease; Biomarkers; Laser capture microdissection, Enfermedad de Alzheimer; Biomarcadores; Microdisección por captura láser, Brain accumulation of amyloid-beta (Aβ) is a crucial feature in Alzheimer´s disease (AD) and cerebral amyloid angiopathy (CAA), although the pathophysiological relationship between these diseases remains unclear. Numerous proteins are associated with Aβ deposited in parenchymal plaques and/or cerebral vessels. We hypothesized that the study of these proteins would increase our understanding of the overlap and biological differences between these two pathologies and may yield new diagnostic tools and specific therapeutic targets. We used a laser capture microdissection approach combined with mass spectrometry in the APP23 transgenic mouse model of cerebral-β-amyloidosis to specifically identify vascular Aβ-associated proteins. We focused on one of the main proteins detected in the Aβ-affected cerebrovasculature: MFG-E8 (milk fat globule-EGF factor 8), also known as lactadherin. We first validated the presence of MFG-E8 in mouse and human brains. Immunofluorescence and immunoblotting studies revealed that MFG-E8 brain levels were higher in APP23 mice than in WT mice. Furthermore, MFG-E8 was strongly detected in Aβ-positive vessels in human postmortem CAA brains, whereas MFG-E8 was not present in parenchymal Aβ deposits. Levels of MFG-E8 were additionally analysed in serum and cerebrospinal fluid (CSF) from patients diagnosed with CAA, patients with AD and control subjects. Whereas no differences were found in MFG-E8 serum levels between groups, MFG-E8 concentration was significantly lower in the CSF of CAA patients compared to controls and AD patients. Finally, in human vascular smooth muscle cells MFG-E8 was protective against the toxic effects of the treatment with the Aβ40 peptide containing the Dutch mutation. In summary, our study shows that MFG-E8 is highly associated with CAA pathology and highlights MFG-E8 as a new CSF biomarker that could potentially be used to differentiate cerebrovascular Aβ pathology from parenchymal Aβ deposition., This work was funded by the Instituto de Salud Carlos III (ISCIII), (PI20/00465), co-financed by the European Regional Development Fund (FEDER). The Neurovascular Research Laboratory is part of the INVICTUS + network, ISCIII, Spain (RD16/0019/0021). P.M. held a predoctoral fellowship from the Vall d’Hebron Research Institute. MMV is supported by the BIONIC project (no. 733050822, which has been made possible by ZonMW as part of ‘Memorabel’, the research and innovation program for dementia, as part of the Dutch national ‘Deltaplan for Dementia’:the CAFÉ project (the National Institutes of Health, USA, grant number 5R01NS104147-02), and a grant from the Selfridges Group Foundation (NR170024). The BIONIC project is a consortium of Radboudumc, LUMC, ADX Neurosciences, and Rhode Island University.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Blood Biomarkers to Predict Long-Term Mortality after Ischemic Stroke

  • Ramiro Pascual, Laura
  • Quintana Luque, Manuel
  • Garcia Rodriguez, Paula
  • Santamarina Pérez, Estevo
  • Alvarez Sabin, José
  • Bustamante Rangel, Alejandro
  • Montaner Villalonga, Joan
  • Abraira del Fresno, Laura
Biomarcador; Endostatina; Accident cerebrovascular isquèmic, Biomarcador; Endostatina; Accidente cerebrovascular isquémico, Biomarker; Endostatin; Ischemic stroke, Stroke is a major cause of disability and death globally, and prediction of mortality represents a crucial challenge. We aimed to identify blood biomarkers measured during acute ischemic stroke that could predict long-term mortality. Nine hundred and forty-one ischemic stroke patients were prospectively recruited in the Stroke-Chip study. Post-stroke mortality was evaluated during a median 4.8-year follow-up. A 14-biomarker panel was analyzed by immunoassays in blood samples obtained at hospital admission. Biomarkers were normalized and standardized using Z-scores. Multiple Cox regression models were used to identify clinical variables and biomarkers independently associated with long-term mortality and mortality due to stroke. In the multivariate analysis, the independent predictors of long-term mortality were age, female sex, hypertension, glycemia, and baseline National Institutes of Health Stroke Scale (NIHSS) score. Independent blood biomarkers predictive of long-term mortality were endostatin > quartile 2, tumor necrosis factor receptor-1 (TNF-R1) > quartile 2, and interleukin (IL)-6 > quartile 2. The risk of mortality when these three biomarkers were combined increased up to 69%. The addition of the biomarkers to clinical predictors improved the discrimination (integrative discriminative improvement (IDI) 0.022 (0.007–0.048), p < 0.001). Moreover, endostatin > quartile 3 was an independent predictor of mortality due to stroke. Altogether, endostatin, TNF-R1, and IL-6 circulating levels may aid in long-term mortality prediction after stroke., This work has been funded by Instituto de Salud Carlos III (PI18/00804) and by La Fundació La Marató (Reg. 84/240 proj. 201702). Neurovascular Research Laboratory takes part in the Spanish stroke research network INVICTUS+ (RD16/0019/0021). L.R. is supported by a pre-doctoral fellowship from the Instituto de Salud Carlos III (IFI17/00012).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer’s Disease

  • Unzeta, Mercedes
  • Hernandez Guillamon, Maria Mar
  • Sun, Ping
  • Solé Piñol, Montserrat
Alzheimer’s disease; Inflammation; Vascular damage, Malaltia d'Alzheimer; Inflamació; Lesions vasculars, Enfermedad de Alzheimer; Inflamación; Lesión vascular, The semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1) or primary amine oxidase (PrAO), is a deaminating enzyme highly expressed in vessels that generates harmful products as a result of its enzymatic activity. As a multifunctional enzyme, it is also involved in inflammation through its ability to bind and promote the transmigration of circulating leukocytes into inflamed tissues. Inflammation is present in different systemic and cerebral diseases, including stroke and Alzheimer’s disease (AD). These pathologies show important affectations on cerebral vessels, together with increased SSAO levels. This review summarizes the main roles of SSAO/VAP-1 in human physiology and pathophysiology and discusses the mechanisms by which it can affect the onset and progression of both stroke and AD. As there is an evident interrelationship between stroke and AD, basically through the vascular system dysfunction, the possibility that SSAO/VAP-1 could be involved in the transition between these two pathologies is suggested. Hence, its inhibition is proposed to be an interesting therapeutical approach to the brain damage induced in these both cerebral pathologies., This research received no external funding. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Blood Biomarker Panels for the Early Prediction of Stroke‐Associated Complications

  • Faura Llorens, Julia
  • Bustamante Rangel, Alejandro
  • Reverté, Silvia
  • Garcia Berrocoso, Teresa
  • Millán Torné, Mònica
  • Castellanos, Mar
  • Ventura Ripoll, Oriol
  • Rubiera Del Fueyo, Marta Aurora
  • Montaner Villalonga, Joan
Biomarkers; Stroke; Stroke‐associated infection, Biomarcadors; Ictus; Infecció associada a un ictus, Biomarcadores; Ictus; Infección asociada a un ictus, Background Acute decompensated heart failure (ADHF) and respiratory tract infections (RTIs) are potentially life‐threatening complications in patients experiencing stroke during hospitalization. We aimed to test whether blood biomarker panels might predict these complications early after admission. Methods and Results Nine hundred thirty‐eight patients experiencing ischemic stroke were prospectively recruited in the Stroke‐Chip study. Post‐stroke complications during hospitalization were retrospectively evaluated. Blood samples were drawn within 6 hours after stroke onset, and 14 biomarkers were analyzed by immunoassays. Biomarker values were normalized using log‐transformation and Z score. PanelomiX algorithm was used to select panels with the best accuracy for predicting ADHF and RTI. Logistic regression models were constructed with the clinical variables and the biomarker panels. The additional predictive value of the panels compared with the clinical model alone was evaluated by receiver operating characteristic curves. An internal validation through a 10‐fold cross‐validation with 3 repeats was performed. ADHF and RTI occurred in 19 (2%) and 86 (9.1%) cases, respectively. Three‐biomarker panels were developed as predictors: vascular adhesion protein‐1 >5.67, NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) >4.98 and d‐dimer >5.38 (sensitivity, 89.5%; specificity, 71.7%) for ADHF; and interleukin‐6 >3.97, von Willebrand factor >3.67, and d‐dimer >4.58 (sensitivity, 82.6%; specificity, 59.8%) for RTI. Both panels independently predicted stroke complications (panel for ADHF: odds ratio [OR] [95% CI], 10.1 [3–52.2]; panel for RTI: OR, 3.73 [1.95–7.14]) after adjustment by clinical confounders. The addition of the panel to clinical predictors significantly improved areas under the curve of the receiver operating characteristic curves in both cases. Conclusions Blood biomarkers could be useful for the early prediction of ADHF and RTI. Future studies should assess the usefulness of these panels in front of patients experiencing stroke with respiratory symptoms such as dyspnea., This project received funding from Instituto de Salud Carlos III (ISCIII) [DTS14/00004, PI17/02130], co‐financed by the European Regional Development Fund (FEDER), and from Fundació La Marató de TV3 [201706] and the European Union's Horizon 2020 research and innovation program [754517]. Neurovascular Research Laboratory takes part into the Spanish stroke research network INVICTUS+ (RD16/0019/0021). The funders had no role in the study design and conduction.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Stroke-induced immunosuppression: implications for the prevention and prediction of post-stroke infections

  • Faura Llorens, Julia
  • Bustamante Rangel, Alejandro
  • Miro Mur, Francesc
  • Montaner Villalonga, Joan
Immunosupressió; Infecció; Ictus, Inmunosupresión; Infección; Ictus, Immunosuppression; Infection; Stroke, Stroke produces a powerful inflammatory cascade in the brain, but also a suppression of the peripheral immune system, which is also called stroke-induced immunosuppression (SIIS). The main processes that lead to SIIS are a shift from a lymphocyte phenotype T-helper (Th) 1 to a Th2 phenotype, a decrease of the lymphocyte counts and NK cells in the blood and spleen, and an impairment of the defense mechanisms of neutrophils and monocytes. The direct clinical consequence of SIIS in stroke patients is an increased susceptibility to stroke-associated infections, which is enhanced by clinical factors like dysphagia. Among these infections, stroke-associated pneumonia (SAP) is the one that accounts for the highest impact on stroke outcome, so research is focused on its early diagnosis and prevention. Biomarkers indicating modifications in SIIS pathways could have an important role in the early prediction of SAP, but currently, there are no individual biomarkers or panels of biomarkers that are accurate enough to be translated to clinical practice. Similarly, there is still no efficient therapy to prevent the onset of SAP, and clinical trials testing prophylactic antibiotic treatment and β-blockers have failed. However, local immunomodulation could open up a new research opportunity to find a preventive therapy for SAP. Recent studies have focused on the pulmonary immune changes that could be caused by stroke similarly to other acquired brain injuries. Some of the traits observed in animal models of stroke include lung edema and inflammation, as well as inflammation of the bronchoalveolar lavage fluid., This project received funding from Instituto de Salud Carlos III (ISCIII) [PI17/02130], co-financed by the European Regional Development Fund (FEDER), and from Fundació La Marató de TV3 [201706]. Neurovascular Research Laboratory takes part into the Spanish stroke research network INVICTUS+ [RD16/0019/0021].
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Identifying new blood biomarkers of neuroplasticity associated with rehabilitation outcomes after stroke

  • García Rodríguez, Nicolás
  • García-Gabilondo, Miguel
  • Rodriguez, Susana
  • Tejada Ezquerro, Pedro Ignacio
  • Miranda-Artieda, Zuberoa Maite
  • Ridao, Natalia
  • Buxo Masip, Xavier
  • Perez-Mesquida, Maria Engracia
  • Valor-Blanquer, Júlia
  • Penalba Morenilla, Anna
  • Pérez, Laura Mónica
  • Inzitari, Marco
  • Lamana Vallverdú, Marcel
  • Delgado Martínez, María Pilar
  • Rosell Novel, Anna
Biomarker; Neuroplasticity; Recovery, Biomarcador; Neuroplasticitat; Recuperació, Biomarcador; Neuroplasticidad; Recuperación, Blood biomarkers in stroke patients seek to guide decision-making in clinical practice, but research on those that respond to brain recovery and their relationship with rehabilitation is still limited. Our aim was to explore the value of known neuroplasticity-related molecules, such as endostatin, growth and differentiation factor-10 (GDF-10), urokinase-type plasminogen activator (uPA) and the uPA receptor (uPAR), as blood biomarkers of recovery during poststroke rehabilitation. In an observational, prospective and multicenter study, biomarker levels were assessed after stroke in a cohort of 62 stroke patients with outcome evaluations and blood sampling before starting rehabilitation and during therapy at 1, 3 and 6 months of first visit, and in 43 control subjects. Serum levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) together with a complete battery of sensorimotor and functional tests/scales: modified Rankin Scale (mRS), Barthel Index (BI), Fugl-Meyer Assessment (FMA) for the upper extremity, Functional Ambulation Categories (FAC), Chedoke Arm and Hand Activity Inventory (CAHAI), 10-m walk test and the Medical Research Council (MRC). Statistical mixed linear models were built to investigate its prognostic value. The results revealed that, compared to controls, only endostatin was significantly increased at baseline after stroke (p < 0.01). Interestingly, the highest baseline GDF-10 or uPAR values were related to unfavorable scores during the complete follow-up (p < 0.05 for walking speed or MRC with GDF-10, and for FMA or MRC with uPAR), whereas decreased endostatin or increased GDF-10 biomarker changes at first month of rehabilitation were related to greater sensorimotor and functional improvements during follow-up (p < 0.05 for FMA or MRC with endostatin, and CAHAI or BI with GDF-10). Our results position endostatin, GDF-10 and uPAR as potential blood biomarkers to monitor recovery during rehabilitation after stroke., N.G-R. is doing a doctorate at the Departament de Medicina de la Universitat Autònoma de Barcelona. Research grants from the Instituto de Salud Carlos III with European Regional Development or Next Generation Founds to A.R. or J.B.S. supported this study (PI16/00981, PI19/00186, RD16/0019/0021, RD16/0019/0008, RD21/0006/0007, and RD21/0006/0014), as well as the 2021-SGR-0656 programme from the Generalitat de Catalunya-AGAUR. N.G-R. received a predoctoral fellowship from VHIR, and MG-G. received a research support grant (PERIS, SLT017/20/000197).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage

  • Marazuela Fuentes, Paula
  • Bonaterra Pastra, Anna
  • Faura Llorens, Julia
  • Penalba Morenilla, Anna
  • Pizarro Gonzálvez, Jesús
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Vert Soler, Carla
  • Rovira Cañellas, Alex
  • Pujadas Navinés, Francesc
  • Montaner Villalonga, Joan
  • Delgado Martínez, Maria Pilar
  • Hernandez Guillamon, Maria Mar
Aquaporina 4; Angiopatia amiloide cerebral; Marcadors d'imatge per ressonància magnètica, Acuaporina 4; Angiopatía amiloide cerebral; Marcadores de imágenes por resonancia magnética, Aquaporin 4; Cerebral amyloid angiopathy; Magnetic resonance imaging markers, Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in elderly patients. Growing evidence suggests a potential role of aquaporin 4 (AQP4) in amyloid-beta-associated diseases, including CAA pathology. Our aim was to investigate the circulating levels of AQP4 in a cohort of patients who had suffered a lobar ICH with a clinical diagnosis of CAA. AQP4 levels were analyzed in the serum of 60 CAA-related ICH patients and 19 non-stroke subjects by enzyme-linked immunosorbent assay (ELISA). The CAA–ICH cohort was divided according to the time point of the functional outcome evaluation: mid-term (12 ± 18.6 months) and long-term (38.5 ± 32.9 months) after the last ICH. Although no differences were found in AQP4 serum levels between cases and controls, lower levels were found in CAA patients presenting specific hemorrhagic features such as ≥2 lobar ICHs and ≥5 lobar microbleeds detected by magnetic resonance imaging (MRI). In addition, CAA-related ICH patients who presented a long-term good functional outcome had higher circulating AQP4 levels than subjects with a poor outcome or controls. Our data suggest that AQP4 could potentially predict a long-term functional outcome and may play a protective role after a lobar ICH., This research was funded by the Instituto de Salud Carlos III (ISCIII), (PI17/00275 and PI20/00465), co-financed by the European Regional Development Fund FEDER. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021). M.H.-G. was supported by the Miguel Servet programme, ISCIII, Spain (CPII17/00010). P.M. held a predoctoral fellowship from the Vall d’Hebron Research Institute.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral β-amyloidosis

  • Fernández-de-Retana, Sofía|||0000-0002-6350-8640
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • Marazuela, Paula|||0000-0003-1038-5242
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Garcia León, Annabel|||0000-0003-3007-9306
  • Montañola, Alex
  • Montaner, Joan|||0000-0003-4845-2279
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Hernández Guillamón, Maria Mar
Cerebral β-amyloidosis is a major feature of Alzheimer's disease (AD), characterized by the accumulation of β-amyloid protein (Aβ) in the brain. Several studies have implicated lipid/lipoprotein metabolism in the regulation of β-amyloidosis. In this regard, HDL (High Density Lipoprotein)-based therapies could ameliorate pathological features associated with AD. As apolipoprotein J (ApoJ) is a natural chaperone that interacts with Aβ, avoiding its aggregation and toxicity, in this study we propose to prepare reconstituted rHDL-rApoJ nanoparticles by assembling phospholipids with recombinant human ApoJ (rApoJ). Hence, rHDL particles were prepared using the cholate dialysis method and characterized by N-PAGE, dynamic light scattering, circular dichroism and electron transmission microscopy. The preparation of rHDL particles showed two-sized populations with discoidal shape. Functionally, rHDL-rApoJ maintained the ability to prevent the Aβ fibrillization and mediated a higher cholesterol efflux from cultured macrophages. Fluorescently-labelled rHDL-rApoJ nanoparticles were intravenously administrated in mice and their distribution over time was determined using an IVIS Xenogen® imager. It was confirmed that rHDL-rApoJ accumulated in the cranial region, especially in old transgenic mice presenting a high cerebral Aβ load. In conclusion, we have standardized a reproducible protocol to produce rHDL-rApoJ nanoparticles, which may be potentially considered as a therapeutic option for β-amyloid-related pathologies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice

  • Fernández-de-Retana, Sofía|||0000-0002-6350-8640
  • Marazuela, Paula|||0000-0003-1038-5242
  • Solé Piñol, Montserrat|||0000-0003-4240-6562
  • Colell, Guillem
  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Montaner, Joan|||0000-0003-4845-2279
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • Hernández Guillamón, Maria Mar
Background: ApoJ/clusterin is a multifunctional protein highly expressed in the brain. The implication of ApoJ in β-amyloid (Aβ) fibrillization and clearance in the context of Alzheimer's disease has been widely studied, although the source and concentration of ApoJ that promotes or inhibits Aβ cerebral accumulation is not clear yet. ApoJ is abundant in plasma and approximately 20% can appear bound to HDL-particles. In this regard, the impact of plasmatic ApoJ and its lipidation status on cerebral β-amyloidosis is still not known. Hence, our main objective was to study the effect of a peripheral increase of free ApoJ or reconstituted HDL particles containing ApoJ in an experimental model of cerebral β-amyloidosis. Methods: Fourteen-month-old APP23 transgenic mice were subjected to subchronic intravenous treatment with rHDL-rApoJ nanodiscs or free rApoJ for 1 month. Aβ concentration and distribution in the brain, as well as Aβ levels in plasma and CSF, were determined after treatments. Other features associated to AD pathology, such as neuronal loss and neuroinflammation, were also evaluated. Results: Both ApoJ-based treatments prevented the Aβ accumulation in cerebral arteries and induced a decrease in total brain insoluble Aβ levels. The peripheral treatment with rApoJ also induced an increase in the Aβ levels in CSF, whereas the concentration remained unaltered in plasma. At all the endpoints studied, the lipidation of rApoJ did not enhance the protective properties of free rApoJ. The effects obtained after subchronic treatment with free rApoJ were accompanied by a reduction in hippocampal neuronal loss and an enhancement of the expression of a phagocytic marker in microglial cells surrounding Aβ deposits. Finally, despite the activation of this phagocytic phenotype, treatments did not induce a global neuroinflammatory status. In fact, free rApoJ treatment was able to reduce the levels of interleukin-17 (IL17) and keratinocyte chemoattractant (KC) chemokine in the brain. Conclusions: Our results demonstrate that an increase in circulating human rApoJ induces a reduction of insoluble Aβ and CAA load in the brain of APP23 mice. Thus, our study suggests that peripheral interventions, based on treatments with multifunctional physiological chaperones, offer therapeutic opportunities to regulate the cerebral Aβ load.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease, Baseline results of the PRECISED study

  • Simó Canonge, Rafael|||0000-0003-0475-3096
  • Bañeras, Jordi|||0000-0002-7395-0862
  • Hernández, Cristina|||0000-0002-3109-1721
  • Rodríguez Palomares, José Fernando|||0000-0002-8822-5532
  • Valente, Filipa|||0000-0002-5569-3292
  • Gutiérrez García-Moreno, Laura
  • González-Alujas, Teresa
  • Ferreira-Gonzalez, Ignacio|||0000-0002-1208-5561
  • Aguadé-Bruix, Santiago|||0000-0001-8617-6274
  • Montaner, Joan|||0000-0003-4845-2279
  • Seron, Daniel|||0000-0003-2054-653X
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
  • Boixadera Espax, Anna
  • García Arumí, José|||0000-0001-8827-1160
  • Planas, Alejandra
  • Simó-Servat, Olga|||0000-0003-3483-652X
  • García-Dorado, David|||0000-0002-1126-1279
Objective Detection of subclinical cardiovascular disease (CVD) has significant impact on the management of type 2 diabetes. We examined whether the assessment of diabetic retinopathy (DR) is useful for identifying patients at a higher risk of having silent CVD. Research design and methods Prospective case-control study comprising 200 type 2 diabetic subjects without history of clinical CVD and 60 age-matched non-diabetic subjects. The presence of subclinical CVD was examined using two parameters: (1) calcium coronary score (CACs); (2) composite of CACs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparison of plasma lipoprotein composition and function in cerebral amyloid angiopathy and Alzheimer's disease

  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Fernández-de-Retana, Sofía|||0000-0002-6350-8640
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Benitez, Sonia|||0000-0003-3565-0743
  • Pancorbo, Olalla|||0000-0003-3240-4862
  • Rodriguez-Luna, David|||0000-0001-8053-4536
  • Pujadas, Francesc|||0000-0003-3569-2601
  • Freijo, Maria del Mar
  • Tur, Silvia
  • Martinez Zabaleta, Maite
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Vera, Rocío
  • Lebrato-Hernández, Lucia|||0000-0002-3541-0697
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Pérez-Sánchez, Soledad|||0000-0002-8940-9763
  • Montaner, Joan|||0000-0003-4845-2279
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
Cerebral amyloid angiopathy (CAA) refers to beta-amyloid (Aβ) deposition in brain vessels and is clinically the main cause of lobar intracerebral hemorrhage (ICH). Aβ can also accumulate in brain parenchyma forming neuritic plaques in Alzheimer's disease (AD). Our study aimed to determine whether the peripheral lipid profile and lipoprotein composition are associated with cerebral beta-amyloidosis pathology and may reflect biological differences in AD and CAA. For this purpose, lipid and apolipoproteins levels were analyzed in plasma from 51 ICH-CAA patients (collected during the chronic phase of the disease), 60 AD patients, and 60 control subjects. Lipoproteins (VLDL, LDL, and HDL) were isolated and their composition and pro/antioxidant ability were determined. We observed that alterations in the lipid profile and lipoprotein composition were remarkable in the ICH-CAA group compared to control subjects, whereas the AD group presented no specific alterations compared with controls. ICH-CAA patients presented an atheroprotective profile, which consisted of lower total and LDL cholesterol levels. Plasma from chronic ICH-CAA patients also showed a redistribution of ApoC-III from HDL to VLDL and a higher ApoE/ApoC-III ratio in HDL. Whether these alterations reflect a protective response or have a causative effect on the pathology requires further investigation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Blood Biomarkers to Predict Long-Term Mortality after Ischemic Stroke

  • Ramiro, Laura|||0000-0002-4121-4609
  • Abraira del Fresno, Laura|||0000-0002-5119-7929
  • Quintana, Manuel|||0000-0003-0288-9088
  • García-Rodríguez, Paula|||0000-0001-6596-8002
  • Santamarina Perez, Estevo|||0000-0003-1915-0335
  • Álvarez Sabín, José|||0000-0002-8054-9209
  • Zaragoza, Josep
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • Ustrell, Xavier
  • Lara-Rodríguez, Blanca|||0009-0003-4534-9687
  • Terceño, Mikel|||0000-0001-5532-5329
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Montaner, Joan|||0000-0003-4845-2279
Stroke is a major cause of disability and death globally, and prediction of mortality represents a crucial challenge. We aimed to identify blood biomarkers measured during acute ischemic stroke that could predict long-term mortality. Nine hundred and forty-one ischemic stroke patients were prospectively recruited in the Stroke-Chip study. Post-stroke mortality was evaluated during a median 4.8-year follow-up. A 14-biomarker panel was analyzed by immunoassays in blood samples obtained at hospital admission. Biomarkers were normalized and standardized using Z -scores. Multiple Cox regression models were used to identify clinical variables and biomarkers independently associated with long-term mortality and mortality due to stroke. In the multivariate analysis, the independent predictors of long-term mortality were age, female sex, hypertension, glycemia, and baseline National Institutes of Health Stroke Scale (NIHSS) score. Independent blood biomarkers predictive of long-term mortality were endostatin.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Blood Biomarker Panels for the Early Prediction of Stroke-Associated Complications

  • Faura, Júlia|||0000-0002-8436-1377
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Reverté, Silvia|||0000-0002-2052-9978
  • García-Berrocoso, Teresa|||0000-0001-7387-7389
  • Millán Torné, Mònica|||0000-0002-4692-5936
  • Castellanos, María del Mar|||0000-0003-3116-1352
  • Lara-Rodríguez, Blanca|||0009-0003-4534-9687
  • Zaragoza, Josep
  • Ventura, Oriol
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • van Eendenburg, Cecile
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • López-Cancio, Elena|||0000-0001-5757-9074
  • Cánovas Verge, David|||0000-0002-3483-8106
  • Serena, Joaquín|||0000-0002-4478-7744
  • Rubiera Del Fueyo, Marta A.|||0000-0001-8100-9477
  • Dávalos, Antoni|||0000-0003-2949-5679
  • Montaner, Joan|||0000-0003-4845-2279
Acute decompensated heart failure (ADHF) and respiratory tract infections (RTIs) are potentially life-threatening complications in patients experiencing stroke during hospitalization. We aimed to test whether blood biomarker panels might predict these complications early after admission. Nine hundred thirty-eight patients experiencing ischemic stroke were prospectively recruited in the Stroke-Chip study. Post-stroke complications during hospitalization were retrospectively evaluated. Blood samples were drawn within 6 hours after stroke onset, and 14 biomarkers were analyzed by immunoassays. Biomarker values were normalized using log-transformation and Z score. PanelomiX algorithm was used to select panels with the best accuracy for predicting ADHF and RTI. Logistic regression models were constructed with the clinical variables and the biomarker panels. The additional predictive value of the panels compared with the clinical model alone was evaluated by receiver operating characteristic curves. An internal validation through a 10-fold cross-validation with 3 repeats was performed. ADHF and RTI occurred in 19 (2%) and 86 (9.1%) cases, respectively. Three-biomarker panels were developed as predictors: vascular adhesion protein-1.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

MRI/Photoluminescence Dual-Modal Imaging Magnetic PLGA Nanocapsules for Theranostics

  • Zhang, Yajie|||0000-0003-1566-1007
  • García-Gabilondo, Miguel|||0000-0002-2015-2621
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Roig i Serra, Anna|||0000-0001-6464-7573
Developing multifunctional and biocompatible drug delivery nanoplatforms that integrate high drug loads and multiple imaging modalities avoiding cross-interferences is extremely challenging. Here we report on the successful chemical reaction of the high quantum yield biodegradable and photoluminescent polyester (BPLP) with the poly(lactic-co-glycolic acid) (PLGA) polymer to fabricate biocompatible photoluminescent nanocapsules (NCs). Furthermore, we transform the PLGA-BPLP NCs into a magnetic resonance (MR)/photoluminescence dual-modal imaging theranostic platform by incorporating superparamagnetic iron oxide nanoparticles (SPIONs) into the polymeric shell. In vitro phantoms confirmed the excellent MRI-r relaxivity values of the NCs whilst the cellular uptake of these NCs was clearly observed by fluorescence optical imaging. Besides, the NCs (mean size ~270 nm) were loaded with ~1 wt% of a model protein (BSA) and their PEGylation provided a more hydrophilic surface. The NCs show biocompatibility in vitro, as hCMEC/D3 endothelial cells viability was not affected for particle concentration up to 500 μg/mL. Interestingly, NCs decorated with SPIONs can be exploited for magnetic guiding and retention.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage

  • Marazuela, Paula|||0000-0003-1038-5242
  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Faura, Júlia|||0000-0002-8436-1377
  • Penalba, Anna
  • Pizarro Gonzálvez, Jesús|||0000-0002-5808-9293
  • Pancorbo, Olalla|||0000-0003-3240-4862
  • Rodriguez-Luna, David|||0000-0001-8053-4536
  • Vert, Carla
  • Rovira, Alex|||0000-0002-2132-6750
  • Pujadas, Francesc|||0000-0003-3569-2601
  • Freijo, M. Mar
  • Tur, Silvia
  • Martínez-Zabaleta, Maite
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Vera, Rocío
  • Lebrato-Hernández, Lucia|||0000-0002-3541-0697
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Pérez-Sánchez, Soledad|||0000-0002-8940-9763
  • Montaner, Joan|||0000-0003-4845-2279
  • Delgado Martínez, María Pilar|||0000-0002-1628-4488
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in elderly patients. Growing evidence suggests a potential role of aquaporin 4 (AQP4) in amyloid-beta-associated diseases, including CAA pathology. Our aim was to investigate the circulating levels of AQP4 in a cohort of patients who had suffered a lobar ICH with a clinical diagnosis of CAA. AQP4 levels were analyzed in the serum of 60 CAA-related ICH patients and 19 non-stroke subjects by enzyme-linked immunosorbent assay (ELISA). The CAA-ICH cohort was divided according to the time point of the functional outcome evaluation: mid-term (12 ± 18.6 months) and long-term (38.5 ± 32.9 months) after the last ICH. Although no differences were found in AQP4 serum levels between cases and controls, lower levels were found in CAA patients presenting specific hemorrhagic features such as ≥2 lobar ICHs and ≥5 lobar microbleeds detected by magnetic resonance imaging (MRI). In addition, CAA-related ICH patients who presented a long-term good functional outcome had higher circulating AQP4 levels than subjects with a poor outcome or controls. Our data suggest that AQP4 could potentially predict a long-term functional outcome and may play a protective role after a lobar ICH.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

SSAO/VAP-1 in Cerebrovascular Disorders, A Potential Therapeutic Target for Stroke and Alzheimer's Disease

  • Unzeta López, Mercedes|||0000-0002-7113-3383
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
  • Sun, Ping|||0000-0001-6307-3723
  • Solé Piñol, Montserrat|||0000-0003-4240-6562
The semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1) or primary amine oxidase (PrAO), is a deaminating enzyme highly expressed in vessels that generates harmful products as a result of its enzymatic activity. As a multifunctional enzyme, it is also involved in inflammation through its ability to bind and promote the transmigration of circulating leukocytes into inflamed tissues. Inflammation is present in different systemic and cerebral diseases, including stroke and Alzheimer's disease (AD). These pathologies show important affectations on cerebral vessels, together with increased SSAO levels. This review summarizes the main roles of SSAO/VAP-1 in human physiology and pathophysiology and discusses the mechanisms by which it can affect the onset and progression of both stroke and AD. As there is an evident interrelationship between stroke and AD, basically through the vascular system dysfunction, the possibility that SSAO/VAP-1 could be involved in the transition between these two pathologies is suggested. Hence, its inhibition is proposed to be an interesting therapeutical approach to the brain damage induced in these both cerebral pathologies
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Stroke-induced immunosuppression, implications for the prevention and prediction of post-stroke infections

  • Faura, Júlia|||0000-0002-8436-1377
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Miró-Mur, Francesc|||0000-0003-3936-2693
  • Montaner, Joan|||0000-0003-4845-2279
Stroke produces a powerful inflammatory cascade in the brain, but also a suppression of the peripheral immune system, which is also called stroke-induced immunosuppression (SIIS). The main processes that lead to SIIS are a shift from a lymphocyte phenotype T-helper (Th) 1 to a Th2 phenotype, a decrease of the lymphocyte counts and NK cells in the blood and spleen, and an impairment of the defense mechanisms of neutrophils and monocytes. The direct clinical consequence of SIIS in stroke patients is an increased susceptibility to stroke-associated infections, which is enhanced by clinical factors like dysphagia. Among these infections, stroke-associated pneumonia (SAP) is the one that accounts for the highest impact on stroke outcome, so research is focused on its early diagnosis and prevention. Biomarkers indicating modifications in SIIS pathways could have an important role in the early prediction of SAP, but currently, there are no individual biomarkers or panels of biomarkers that are accurate enough to be translated to clinical practice. Similarly, there is still no efficient therapy to prevent the onset of SAP, and clinical trials testing prophylactic antibiotic treatment and β-blockers have failed. However, local immunomodulation could open up a new research opportunity to find a preventive therapy for SAP. Recent studies have focused on the pulmonary immune changes that could be caused by stroke similarly to other acquired brain injuries. Some of the traits observed in animal models of stroke include lung edema and inflammation, as well as inflammation of the bronchoalveolar lavage fluid.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Survival Bias and Crosstalk between Chronological and Behavioral Age, Age- and Genotype-Sensitivity Tests Define Behavioral Signatures in Middle-Aged, Old, and Long-Lived Mice with Normal and AD-Associated Aging

  • Gimenez-Llort, Lydia|||0000-0002-4091-489X
  • Marín-Pardo, Daniela|||0000-0002-0202-0334
  • Marazuela, Paula|||0000-0003-1038-5242
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
New evidence refers to a high degree of heterogeneity in normal but also Alzheimer's disease (AD) clinical and temporal patterns, increased mortality, and the need to find specific end-of-life prognosticators. This heterogeneity is scarcely explored in very old male AD mice models due to their reduced survival. In the present work, using 915 (432 APP23 and 483 C57BL/6 littermates) mice, we confirmed the better survival curves in male than female APP23 mice and respective wildtypes, providing the chance to characterize behavioral signatures in middle-aged, old, and long-lived male animals. The sensitivity of a battery of seven paradigms for comprehensive screening of motor (activity and gait analysis), neuropsychiatric and cognitive symptoms was analyzed using a cohort of 56 animals, composed of 12-, 18- and 24-month-old male APP23 mice and wildtype littermates. Most variables analyzed detected age-related differences. However, variables related to coping with stress, thigmotaxis, frailty, gait, and poor cognition better discriminated the behavioral phenotype of male APP23 mice through the three old ages compared with controls. Most importantly, non-linear age- and genotype-dependent behavioral signatures were found in long-lived animals, suggesting crosstalk between chronological and biological/behavioral ages useful to study underlying mechanisms and distinct compensations through physiological and AD-associated aging.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Angiogenin in the Neurogenic Subventricular Zone After Stroke

  • Gabriel Salazar, Marina|||0000-0002-7521-1502
  • Lei, Ting|||0000-0002-2787-5208
  • Grayston, Alba|||0000-0002-1466-0099
  • Costa, Carme|||0000-0001-9577-3839
  • Medina-Gutiérrez, Esperanza
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Montaner, Joan|||0000-0003-4845-2279
  • Rosell Novel, Anna|||0000-0003-1082-3599
Ischemic stroke is a leading cause of death and disability worldwide with effective acute thrombolytic treatments. However, brain repair mechanisms related to spontaneous or rehabilitation-induced recovery are still under investigation, and little is known about the molecules involved. The present study examines the potential role of angiogenin (ANG), a known regulator of cell function and metabolism linked to neurological disorders, focusing in the neurogenic subventricular zone (SVZ). Angiogenin expression was examined in the mouse SVZ and in SVZ-derived neural stem cells (NSCs), which were exposed to exogenous ANG treatment during neurosphere formation as well as in other neuron-like cells (SH-SY5Y). Additionally, male C57Bl/6 mice underwent a distal permanent occlusion of the middle cerebral artery to study endogenous and exercise-induced expression of SVZ-ANG and neuroblast migration. Our results show that SVZ areas are rich in ANG, primarily expressed in DCX+ neuroblasts but not in nestin+NSCs. In vitro, treatment with ANG increased the number of SVZ-derived NSCs forming neurospheres but could not modify SH-SY5Y neurite differentiation. Finally, physical exercise rapidly increased the amount of endogenous ANG in the ipsilateral SVZ niche after ischemia, where DCX-migrating cells increased as part of the post-stroke neurogenesis process. Our findings position for the first time ANG in the SVZ during post-stroke recovery, which could be linked to neurogenesis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Sleep/wake cycle alterations as a cause of neurodegenerative diseases, A Mendelian randomization study

  • Cullell, Natalia|||0000-0001-5118-1014
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Muiño, Elena|||0000-0001-5839-7328
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Lledós, Miquel|||0000-0001-8832-789X
  • Amaut, K.E.U.
  • Krupinski, J.
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Sleep and/or wake cycle alterations are common in neurodegenerative diseases (ND). Our aim was to determine whether there is a causal relationship between sleep and/or wake cycle patterns and ND (Parkinson's disease (PD) age at onset (AAO), Alzheimer's disease (AD), and amyotrophic lateral sclerosis (ALS)) using two-sample Mendelian Randomization (MR). We selected 12 sleep traits with available Genome-Wide Association Study (GWAS) to evaluate their causal relationship with the ND risk through Inverse-Variance Weighted regression as main analysis. We used as outcome the latest ND GWAS with available summary-statistics: PD-AAO (N = 17,996), AD (N = 21,235) and ALS (N = 40,136). MR results pointed to a causal effect of subjective and objective-measured morning chronotype on later PD-AAO (95%CI:0.33-1.81, p = 8.47×10 and 95%CI:-7.28 to -4.44, p = 5.87×10, respectively). Sleep efficiency was causally associated with a decreased AD risk (95%CI:-20.408 to -0.66, p = 0.04) and daytime sleepiness with an increased ALS risk (95%CI:0.15 to 1.61, p = 0.01). Our study suggests that sleep and/or wake patterns have causal relationship with ND. Given that sleep and/or wake patterns are modifiable risk factors, sleep interventions should be investigated as a potential treatment in PD-AAO, AD and ALS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Functional Recovery and Serum Angiogenin Changes According to Intensity of Rehabilitation Therapy After Stroke

  • García Rodríguez, Nicolás|||0000-0001-8839-0514
  • Rodriguez Gonzalez, Susana|||0000-0002-6170-5253
  • Tejada, Pedro Ignacio
  • Miranda-Artieda, Zuberoa Maite
  • Ridao, Natalia
  • Buxo Masip, Xavier|||0000-0001-6814-7373
  • Pérez-Mesquida, María Engracia|||0000-0001-7949-7678
  • Beseler, Maria Rosario
  • Salom, Juan B.|||0000-0002-4162-6101
  • Pérez, Laura Mónica|||0000-0003-3152-9882
  • Inzitari, Marco|||0000-0002-3796-0625
  • Otero-Villaverde, Sergio
  • Martin-Mourelle, Rosa
  • Molleda, Mercedes|||0000-0001-5393-9837
  • Quintana, Manuel|||0000-0003-0288-9088
  • Olivé-Gadea, Marta|||0000-0003-4637-1598
  • Penalba, Anna
  • Rosell Novel, Anna|||0000-0003-1082-3599
Rehabilitation is still the only treatment available to improve functional status after the acute phase of stroke. Most clinical guidelines highlight the need to design rehabilitation treatments considering starting time, intensity, and frequency, according to the tolerance of the patient. However, there are no homogeneous protocols and the biological effects are under investigation. To investigate the impact of rehabilitation intensity (hours) after stroke on functional improvement and serum angiogenin (ANG) in a 6-month follow-up study. A prospective, observational, longitudinal, and multicenter study with three cohorts: strokes in intensive rehabilitation therapy (IRT, minimum 15 h/week) vs. conventional therapy (NO-IRT, <15 h/week), and controls subjects (without known neurological, malignant, or inflammatory diseases). A total of seven centers participated, with functional evaluations and blood sampling during follow-up. The final cohort includes 62 strokes and 43 controls with demographic, clinical, blood samples, and exhaustive functional monitoring. The median (IQR) number of weekly hours of therapy was different: IRT 15 (15-16) vs. NO-IRT 7.5 (5-9), p < 0.01, with progressive and significant improvements in both groups. However, IRT patients showed earlier improvements (within 1 month) on several scales (CAHAI, FMA, and FAC; p < 0.001) and the earliest community ambulation achievements (0.89 m/s at 3 months). There was a significant difference in ANG temporal profile between the IRT and NO-IRT groups (p < 0.01). Additionally, ANG was elevated at 1 month only in the IRT group (p < 0.05) whereas it decreased in the NO-IRT group (p < 0.05). Our results suggest an association of rehabilitation intensity with early functional improvements, and connect the rehabilitation process with blood biomarkers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genome-Wide Association Study of VKORC1 and CYP2C9 on acenocoumarol dose, stroke recurrence and intracranial haemorrhage in Spain

  • Cullell, Natalia|||0000-0001-5118-1014
  • Carrera, Caty|||0000-0002-0804-0969
  • Muiño, Elena|||0000-0001-5839-7328
  • Torres-Aguila, Nuria|||0000-0002-9502-9310
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • González-Sánchez, Jonathan
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Molina, Jessica
  • Besora, Sarah
  • Sotoca Fernández, Javier|||0000-0003-3400-1434
  • Buongiorno, María-Teresa
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Giralt Steinhauer, Eva|||0000-0002-7463-0983
  • de Torres-Chacón, Reyes
  • Montaner, Joan|||0000-0003-4845-2279
  • Mancha, Fernando|||0000-0003-0310-0894
  • Cabezas, Juan Antonio
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Purroy, Francisco|||0000-0002-1808-5968
  • Cambray, Serafi
  • Freijo, María del Mar
  • Vives-Bauzá, Cristòfol|||0000-0001-5735-8335
  • Tur, Silvia
  • Font, Maria-Àngels
  • López-Cancio, Elena|||0000-0001-5757-9074
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • Obach, Víctor|||0000-0002-0518-1053
  • Calleja, Ana
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Rodríguez-Yáñez, Manuel
  • Castillo, José
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Krupinski, Jerzy|||0000-0002-5136-8898
Acenocoumarol is an oral anticoagulant with significant interindividual dose variations. Variants in CYP2C9 and VKORC1 have been associated with acenocoumarol maintenance dose. We analysed whether any of the 49 polymorphisms in CYP2C9 and VKORC1 previously associated with acenocoumarol maintenance dose in a Genome-Wide Association study (GWAs) in Dutch population are associated with stroke recurrence, intracranial haemorrhage (ICH) and acenocoumarol maintenance dose in a Spanish population. We performed a GWAs using Human Core Exome-chip (Illumina) in 78 patients stroke patients treated with acenocoumarol for secondary prevention enrolled as part of the prospective investigator-initiated study (IIS) SEDMAN Study. Patients were followed-up a median of 12.8 months. Three and eight patients had recurrent stroke and ICH events, respectively. We found 14 of the 49 published variants associated with acenocoumarol maintenance dose (p < 0.05). Six polymorphisms were associated with stroke recurrence and four variants with ICH (p < 0.05). In conclusion, variants in VKORC1 and CYP2C9 are associated with acenocoumarol maintenance dose, stroke recurrence and ICH in a Spanish cohort. These results highlight the relevance of studying pharmacogenetics associated with efficacy and safety of anticoagulant drugs and justify studies with larger sample size and different ethnic populations.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer's disease

  • Camacho, Jessica|||0000-0001-8018-8274
  • Rábano, Alberto|||0000-0001-9320-6566
  • Marazuela, Paula|||0000-0003-1038-5242
  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Serna, Garazi|||0000-0003-2666-0982
  • Moliné, Teresa|||0000-0003-4912-5114
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • Martinez-Saez, Elena|||0000-0001-6004-5364
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
Genome-wide association studies have described several genes as genetic susceptibility loci for Alzheimer's disease (AD). Among them, CD2AP encodes CD2-associated protein, a scaffold protein implicated in dynamic actin remodeling and membrane trafficking during endocytosis and cytokinesis. Although a clear link between CD2AP defects and glomerular pathology has been described, little is known about the function of CD2AP in the brain. The aim of this study was to analyze the distribution of CD2AP in the AD brain and its potential associations with tau aggregation and β-amyloid (Aβ) deposition. First, we performed immunohistochemical analysis of CD2AP expression in brain tissue from AD patients and controls (N = 60). Our results showed granular CD2AP immunoreactivity in the human brain endothelium in all samples. In AD cases, no CD2AP was found to be associated with Aβ deposits in vessels or parenchymal plaques. CD2AP neuronal inclusions similar to neurofibrillary tangles (NFT) and neuropil thread-like deposits were found only in AD samples. Moreover, immunofluorescence analysis revealed that CD2AP colocalized with pTau. Regarding CD2AP neuronal distribution, a hierarchical progression from the entorhinal to the temporal and occipital cortex was detected. We found that CD2AP immunodetection in neurons was strongly and positively associated with Braak neurofibrillary stage, independent of age and other pathological hallmarks. To further investigate the association between pTau and CD2AP, we included samples from cases of primary tauopathies (corticobasal degeneration [CBD], progressive supranuclear palsy [PSP], and Pick's disease [PiD]) in our study. Among these cases, CD2AP positivity was only found in PiD samples as neurofibrillary tangle-like and Pick body-like deposits, whereas no neuronal CD2AP deposits were detected in PSP or CBD samples, which suggested an association of CD2AP neuronal expression with 3R-Tau-diseases. In conclusion, our findings open a new road to investigate the complex cellular mechanism underlying the tangle conformation and tau pathology in the brain.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Stroke-induced immunosuppression: implications for the prevention and prediction of post-stroke infections

  • Faura Llorens, Julia
  • Bustamante Rangel, Alejandro
  • Miro Mur, Francesc
  • Montaner Villalonga, Joan
Immunosupressió; Infecció; Ictus, Inmunosupresión; Infección; Ictus, Immunosuppression; Infection; Stroke, Stroke produces a powerful inflammatory cascade in the brain, but also a suppression of the peripheral immune system, which is also called stroke-induced immunosuppression (SIIS). The main processes that lead to SIIS are a shift from a lymphocyte phenotype T-helper (Th) 1 to a Th2 phenotype, a decrease of the lymphocyte counts and NK cells in the blood and spleen, and an impairment of the defense mechanisms of neutrophils and monocytes. The direct clinical consequence of SIIS in stroke patients is an increased susceptibility to stroke-associated infections, which is enhanced by clinical factors like dysphagia. Among these infections, stroke-associated pneumonia (SAP) is the one that accounts for the highest impact on stroke outcome, so research is focused on its early diagnosis and prevention. Biomarkers indicating modifications in SIIS pathways could have an important role in the early prediction of SAP, but currently, there are no individual biomarkers or panels of biomarkers that are accurate enough to be translated to clinical practice. Similarly, there is still no efficient therapy to prevent the onset of SAP, and clinical trials testing prophylactic antibiotic treatment and β-blockers have failed. However, local immunomodulation could open up a new research opportunity to find a preventive therapy for SAP. Recent studies have focused on the pulmonary immune changes that could be caused by stroke similarly to other acquired brain injuries. Some of the traits observed in animal models of stroke include lung edema and inflammation, as well as inflammation of the bronchoalveolar lavage fluid., This project received funding from Instituto de Salud Carlos III (ISCIII) [PI17/02130], co-financed by the European Regional Development Fund (FEDER), and from Fundació La Marató de TV3 [201706]. Neurovascular Research Laboratory takes part into the Spanish stroke research network INVICTUS+ [RD16/0019/0021].
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy

  • Marazuela Fuentes, Paula
  • Solé Piñol, Montserrat
  • Bonaterra Pastra, Anna
  • Pizarro Gonzálvez, Jesús
  • Camacho Soriano, Jessica
  • Martinez Saez, Elena Antima
  • Castillo Ribelles, Laura
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Pujadas Navinés, Francesc
  • Delgado Martínez, Maria Pilar
  • Hernandez Guillamon, Maria Mar
Malaltia d'Alzheimer; Biomarcadors; Microdissecció de captura làser, Alzheimer's disease; Biomarkers; Laser capture microdissection, Enfermedad de Alzheimer; Biomarcadores; Microdisección por captura láser, Brain accumulation of amyloid-beta (Aβ) is a crucial feature in Alzheimer´s disease (AD) and cerebral amyloid angiopathy (CAA), although the pathophysiological relationship between these diseases remains unclear. Numerous proteins are associated with Aβ deposited in parenchymal plaques and/or cerebral vessels. We hypothesized that the study of these proteins would increase our understanding of the overlap and biological differences between these two pathologies and may yield new diagnostic tools and specific therapeutic targets. We used a laser capture microdissection approach combined with mass spectrometry in the APP23 transgenic mouse model of cerebral-β-amyloidosis to specifically identify vascular Aβ-associated proteins. We focused on one of the main proteins detected in the Aβ-affected cerebrovasculature: MFG-E8 (milk fat globule-EGF factor 8), also known as lactadherin. We first validated the presence of MFG-E8 in mouse and human brains. Immunofluorescence and immunoblotting studies revealed that MFG-E8 brain levels were higher in APP23 mice than in WT mice. Furthermore, MFG-E8 was strongly detected in Aβ-positive vessels in human postmortem CAA brains, whereas MFG-E8 was not present in parenchymal Aβ deposits. Levels of MFG-E8 were additionally analysed in serum and cerebrospinal fluid (CSF) from patients diagnosed with CAA, patients with AD and control subjects. Whereas no differences were found in MFG-E8 serum levels between groups, MFG-E8 concentration was significantly lower in the CSF of CAA patients compared to controls and AD patients. Finally, in human vascular smooth muscle cells MFG-E8 was protective against the toxic effects of the treatment with the Aβ40 peptide containing the Dutch mutation. In summary, our study shows that MFG-E8 is highly associated with CAA pathology and highlights MFG-E8 as a new CSF biomarker that could potentially be used to differentiate cerebrovascular Aβ pathology from parenchymal Aβ deposition., This work was funded by the Instituto de Salud Carlos III (ISCIII), (PI20/00465), co-financed by the European Regional Development Fund (FEDER). The Neurovascular Research Laboratory is part of the INVICTUS + network, ISCIII, Spain (RD16/0019/0021). P.M. held a predoctoral fellowship from the Vall d’Hebron Research Institute. MMV is supported by the BIONIC project (no. 733050822, which has been made possible by ZonMW as part of ‘Memorabel’, the research and innovation program for dementia, as part of the Dutch national ‘Deltaplan for Dementia’:the CAFÉ project (the National Institutes of Health, USA, grant number 5R01NS104147-02), and a grant from the Selfridges Group Foundation (NR170024). The BIONIC project is a consortium of Radboudumc, LUMC, ADX Neurosciences, and Rhode Island University.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Blood Biomarker Panels for the Early Prediction of Stroke‐Associated Complications

  • Faura Llorens, Julia
  • Bustamante Rangel, Alejandro
  • Reverté, Silvia
  • Garcia Berrocoso, Teresa
  • Millán Torné, Mònica
  • Castellanos, Mar
  • Ventura Ripoll, Oriol
  • Rubiera Del Fueyo, Marta Aurora
  • Montaner Villalonga, Joan
Biomarkers; Stroke; Stroke‐associated infection, Biomarcadors; Ictus; Infecció associada a un ictus, Biomarcadores; Ictus; Infección asociada a un ictus, Background Acute decompensated heart failure (ADHF) and respiratory tract infections (RTIs) are potentially life‐threatening complications in patients experiencing stroke during hospitalization. We aimed to test whether blood biomarker panels might predict these complications early after admission. Methods and Results Nine hundred thirty‐eight patients experiencing ischemic stroke were prospectively recruited in the Stroke‐Chip study. Post‐stroke complications during hospitalization were retrospectively evaluated. Blood samples were drawn within 6 hours after stroke onset, and 14 biomarkers were analyzed by immunoassays. Biomarker values were normalized using log‐transformation and Z score. PanelomiX algorithm was used to select panels with the best accuracy for predicting ADHF and RTI. Logistic regression models were constructed with the clinical variables and the biomarker panels. The additional predictive value of the panels compared with the clinical model alone was evaluated by receiver operating characteristic curves. An internal validation through a 10‐fold cross‐validation with 3 repeats was performed. ADHF and RTI occurred in 19 (2%) and 86 (9.1%) cases, respectively. Three‐biomarker panels were developed as predictors: vascular adhesion protein‐1 >5.67, NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) >4.98 and d‐dimer >5.38 (sensitivity, 89.5%; specificity, 71.7%) for ADHF; and interleukin‐6 >3.97, von Willebrand factor >3.67, and d‐dimer >4.58 (sensitivity, 82.6%; specificity, 59.8%) for RTI. Both panels independently predicted stroke complications (panel for ADHF: odds ratio [OR] [95% CI], 10.1 [3–52.2]; panel for RTI: OR, 3.73 [1.95–7.14]) after adjustment by clinical confounders. The addition of the panel to clinical predictors significantly improved areas under the curve of the receiver operating characteristic curves in both cases. Conclusions Blood biomarkers could be useful for the early prediction of ADHF and RTI. Future studies should assess the usefulness of these panels in front of patients experiencing stroke with respiratory symptoms such as dyspnea., This project received funding from Instituto de Salud Carlos III (ISCIII) [DTS14/00004, PI17/02130], co‐financed by the European Regional Development Fund (FEDER), and from Fundació La Marató de TV3 [201706] and the European Union's Horizon 2020 research and innovation program [754517]. Neurovascular Research Laboratory takes part into the Spanish stroke research network INVICTUS+ (RD16/0019/0021). The funders had no role in the study design and conduction.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

SSAO/VAP-1 in Cerebrovascular Disorders: A Potential Therapeutic Target for Stroke and Alzheimer’s Disease

  • Unzeta, Mercedes
  • Hernandez Guillamon, Maria Mar
  • Sun, Ping
  • Solé Piñol, Montserrat
Alzheimer’s disease; Inflammation; Vascular damage, Malaltia d'Alzheimer; Inflamació; Lesions vasculars, Enfermedad de Alzheimer; Inflamación; Lesión vascular, The semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1) or primary amine oxidase (PrAO), is a deaminating enzyme highly expressed in vessels that generates harmful products as a result of its enzymatic activity. As a multifunctional enzyme, it is also involved in inflammation through its ability to bind and promote the transmigration of circulating leukocytes into inflamed tissues. Inflammation is present in different systemic and cerebral diseases, including stroke and Alzheimer’s disease (AD). These pathologies show important affectations on cerebral vessels, together with increased SSAO levels. This review summarizes the main roles of SSAO/VAP-1 in human physiology and pathophysiology and discusses the mechanisms by which it can affect the onset and progression of both stroke and AD. As there is an evident interrelationship between stroke and AD, basically through the vascular system dysfunction, the possibility that SSAO/VAP-1 could be involved in the transition between these two pathologies is suggested. Hence, its inhibition is proposed to be an interesting therapeutical approach to the brain damage induced in these both cerebral pathologies., This research received no external funding. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer’s disease

  • Camacho Soriano, Jessica
  • Rábano, Alberto
  • Marazuela Fuentes, Paula
  • Bonaterra Pastra, Anna
  • Serna Alonso, Garazi
  • Moline Marimon, Teresa
  • Ramon y Cajal Agüeras, Santiago
  • Martinez Saez, Elena Antima
  • Hernandez Guillamon, Maria Mar
Alzheimer; CD2AP; Enfermedad de Pick, Alzheimer's disease; CD2AP; Pick's disease, Alzheimer; CD2AP; Malaltia de Pick, Genome-wide association studies have described several genes as genetic susceptibility loci for Alzheimer's disease (AD). Among them, CD2AP encodes CD2-associated protein, a scaffold protein implicated in dynamic actin remodeling and membrane trafficking during endocytosis and cytokinesis. Although a clear link between CD2AP defects and glomerular pathology has been described, little is known about the function of CD2AP in the brain. The aim of this study was to analyze the distribution of CD2AP in the AD brain and its potential associations with tau aggregation and β-amyloid (Aβ) deposition. First, we performed immunohistochemical analysis of CD2AP expression in brain tissue from AD patients and controls (N = 60). Our results showed granular CD2AP immunoreactivity in the human brain endothelium in all samples. In AD cases, no CD2AP was found to be associated with Aβ deposits in vessels or parenchymal plaques. CD2AP neuronal inclusions similar to neurofibrillary tangles (NFT) and neuropil thread-like deposits were found only in AD samples. Moreover, immunofluorescence analysis revealed that CD2AP colocalized with pTau. Regarding CD2AP neuronal distribution, a hierarchical progression from the entorhinal to the temporal and occipital cortex was detected. We found that CD2AP immunodetection in neurons was strongly and positively associated with Braak neurofibrillary stage, independent of age and other pathological hallmarks. To further investigate the association between pTau and CD2AP, we included samples from cases of primary tauopathies (corticobasal degeneration [CBD], progressive supranuclear palsy [PSP], and Pick's disease [PiD]) in our study. Among these cases, CD2AP positivity was only found in PiD samples as neurofibrillary tangle-like and Pick body-like deposits, whereas no neuronal CD2AP deposits were detected in PSP or CBD samples, which suggested an association of CD2AP neuronal expression with 3R-Tau-diseases. In conclusion, our findings open a new road to investigate the complex cellular mechanism underlying the tangle conformation and tau pathology in the brain., This work was funded by Instituto de Salud Carlos III (ISCIII) (PI17/00275, PI20/00465), cofinanced by the European Regional Development Fund (FEDER). The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021). M.H.-G. is supported by the Miguel Servet Programme, ISCIII, Spain (CPII17/00010)
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage

  • Marazuela Fuentes, Paula
  • Bonaterra Pastra, Anna
  • Faura Llorens, Julia
  • Penalba Morenilla, Anna
  • Pizarro Gonzálvez, Jesús
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Vert Soler, Carla
  • Rovira, Alex
  • Pujadas Navinés, Francesc
  • Montaner Villalonga, Joan
  • Delgado Martínez, Maria Pilar
  • Hernandez Guillamon, Maria Mar
Aquaporina 4; Angiopatia amiloide cerebral; Marcadors d'imatge per ressonància magnètica, Acuaporina 4; Angiopatía amiloide cerebral; Marcadores de imágenes por resonancia magnética, Aquaporin 4; Cerebral amyloid angiopathy; Magnetic resonance imaging markers, Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in elderly patients. Growing evidence suggests a potential role of aquaporin 4 (AQP4) in amyloid-beta-associated diseases, including CAA pathology. Our aim was to investigate the circulating levels of AQP4 in a cohort of patients who had suffered a lobar ICH with a clinical diagnosis of CAA. AQP4 levels were analyzed in the serum of 60 CAA-related ICH patients and 19 non-stroke subjects by enzyme-linked immunosorbent assay (ELISA). The CAA–ICH cohort was divided according to the time point of the functional outcome evaluation: mid-term (12 ± 18.6 months) and long-term (38.5 ± 32.9 months) after the last ICH. Although no differences were found in AQP4 serum levels between cases and controls, lower levels were found in CAA patients presenting specific hemorrhagic features such as ≥2 lobar ICHs and ≥5 lobar microbleeds detected by magnetic resonance imaging (MRI). In addition, CAA-related ICH patients who presented a long-term good functional outcome had higher circulating AQP4 levels than subjects with a poor outcome or controls. Our data suggest that AQP4 could potentially predict a long-term functional outcome and may play a protective role after a lobar ICH., This research was funded by the Instituto de Salud Carlos III (ISCIII), (PI17/00275 and PI20/00465), co-financed by the European Regional Development Fund FEDER. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021). M.H.-G. was supported by the Miguel Servet programme, ISCIII, Spain (CPII17/00010). P.M. held a predoctoral fellowship from the Vall d’Hebron Research Institute.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Functional Recovery and Serum Angiogenin Changes According to Intensity of Rehabilitation Therapy After Stroke

  • Garcia Rodriguez, Nicolas
  • Rodriguez Gonzalez, Susana
  • Ignacio Tejada, Pedro
  • Miranda-Artieda, Zuberoa Maite
  • Ridao, Natalia
  • Buxo Masip, Xavier
  • Perez Bazan, Laura Mónica
  • Quintana Luque, Manuel
  • Olive Gadea, Marta
  • Penalba Morenilla, Anna
  • Rosell Novel, Anna
  • Inzitari, Marco
  • Perez-Mesquida, Maria Engracia
Angiogenina; Terapia intensiva; Rehabilitación, Angiogenin; Intensive therapy; Rehabilitation, Angiogenina; Teràpia intensiva; Rehabilitació, Background: Rehabilitation is still the only treatment available to improve functional status after the acute phase of stroke. Most clinical guidelines highlight the need to design rehabilitation treatments considering starting time, intensity, and frequency, according to the tolerance of the patient. However, there are no homogeneous protocols and the biological effects are under investigation. Objective: To investigate the impact of rehabilitation intensity (hours) after stroke on functional improvement and serum angiogenin (ANG) in a 6-month follow-up study. Methods: A prospective, observational, longitudinal, and multicenter study with three cohorts: strokes in intensive rehabilitation therapy (IRT, minimum 15 h/week) vs. conventional therapy (NO-IRT, <15 h/week), and controls subjects (without known neurological, malignant, or inflammatory diseases). A total of seven centers participated, with functional evaluations and blood sampling during follow-up. The final cohort includes 62 strokes and 43 controls with demographic, clinical, blood samples, and exhaustive functional monitoring. Results: The median (IQR) number of weekly hours of therapy was different: IRT 15 (15–16) vs. NO-IRT 7.5 (5–9), p < 0.01, with progressive and significant improvements in both groups. However, IRT patients showed earlier improvements (within 1 month) on several scales (CAHAI, FMA, and FAC; p < 0.001) and the earliest community ambulation achievements (0.89 m/s at 3 months). There was a significant difference in ANG temporal profile between the IRT and NO-IRT groups (p < 0.01). Additionally, ANG was elevated at 1 month only in the IRT group (p < 0.05) whereas it decreased in the NO-IRT group (p < 0.05). Conclusions: Our results suggest an association of rehabilitation intensity with early functional improvements, and connect the rehabilitation process with blood biomarkers., NG-R holds a VHIR fellowship and MO-G a Joan Margarit VHIR fellowship. Research grants: from the Instituto de Salud Carlos III and European Regional Development Funds (PI16/00981, PI19/00186, RD16/0019/0021, and RD16/0019/0008), 2017-SGR-1427 program from the Generalitat de Catalunya-AGAUR, and Clinical Translational Program for Regenerative Medicine in Catalonia (P-CMR [C]).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Blood Biomarkers to Predict Long-Term Mortality after Ischemic Stroke

  • Ramiro Pascual, Laura
  • Quintana Luque, Manuel
  • Garcia Rodriguez, Paula
  • Santamarina Pérez, Estevo
  • Alvarez Sabin, José
  • Bustamante Rangel, Alejandro
  • Montaner Villalonga, Joan
  • Abraira del Fresno, Laura
Biomarcador; Endostatina; Accident cerebrovascular isquèmic, Biomarcador; Endostatina; Accidente cerebrovascular isquémico, Biomarker; Endostatin; Ischemic stroke, Stroke is a major cause of disability and death globally, and prediction of mortality represents a crucial challenge. We aimed to identify blood biomarkers measured during acute ischemic stroke that could predict long-term mortality. Nine hundred and forty-one ischemic stroke patients were prospectively recruited in the Stroke-Chip study. Post-stroke mortality was evaluated during a median 4.8-year follow-up. A 14-biomarker panel was analyzed by immunoassays in blood samples obtained at hospital admission. Biomarkers were normalized and standardized using Z-scores. Multiple Cox regression models were used to identify clinical variables and biomarkers independently associated with long-term mortality and mortality due to stroke. In the multivariate analysis, the independent predictors of long-term mortality were age, female sex, hypertension, glycemia, and baseline National Institutes of Health Stroke Scale (NIHSS) score. Independent blood biomarkers predictive of long-term mortality were endostatin > quartile 2, tumor necrosis factor receptor-1 (TNF-R1) > quartile 2, and interleukin (IL)-6 > quartile 2. The risk of mortality when these three biomarkers were combined increased up to 69%. The addition of the biomarkers to clinical predictors improved the discrimination (integrative discriminative improvement (IDI) 0.022 (0.007–0.048), p < 0.001). Moreover, endostatin > quartile 3 was an independent predictor of mortality due to stroke. Altogether, endostatin, TNF-R1, and IL-6 circulating levels may aid in long-term mortality prediction after stroke., This work has been funded by Instituto de Salud Carlos III (PI18/00804) and by La Fundació La Marató (Reg. 84/240 proj. 201702). Neurovascular Research Laboratory takes part in the Spanish stroke research network INVICTUS+ (RD16/0019/0021). L.R. is supported by a pre-doctoral fellowship from the Instituto de Salud Carlos III (IFI17/00012).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer’s Disease

  • Bonaterra Pastra, Anna
  • Fernández de Retana, Sofía
  • Rivas-Urbina, Andrea
  • Puig, Núria
  • Benítez, Sònia
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Pujadas Navinés, Francesc
  • Montaner Villalonga, Joan
  • Hernandez Guillamon, Maria Mar
Malaltia d'Alzheimer; Apolipoproteïnes; Angiopatia amiloide cerebral, Enfermedad de Alzheimer; Apolipoproteínas; Angiopatía amiloide cerebral, Alzheimer’s disease; Apolipoproteins; Cerebral amyloid angiopathy, Cerebral amyloid angiopathy (CAA) refers to beta-amyloid (Aβ) deposition in brain vessels and is clinically the main cause of lobar intracerebral hemorrhage (ICH). Aβ can also accumulate in brain parenchyma forming neuritic plaques in Alzheimer’s disease (AD). Our study aimed to determine whether the peripheral lipid profile and lipoprotein composition are associated with cerebral beta-amyloidosis pathology and may reflect biological differences in AD and CAA. For this purpose, lipid and apolipoproteins levels were analyzed in plasma from 51 ICH-CAA patients (collected during the chronic phase of the disease), 60 AD patients, and 60 control subjects. Lipoproteins (VLDL, LDL, and HDL) were isolated and their composition and pro/antioxidant ability were determined. We observed that alterations in the lipid profile and lipoprotein composition were remarkable in the ICH-CAA group compared to control subjects, whereas the AD group presented no specific alterations compared with controls. ICH-CAA patients presented an atheroprotective profile, which consisted of lower total and LDL cholesterol levels. Plasma from chronic ICH-CAA patients also showed a redistribution of ApoC-III from HDL to VLDL and a higher ApoE/ApoC-III ratio in HDL. Whether these alterations reflect a protective response or have a causative effect on the pathology requires further investigation., This research was funded by Instituto de Salud Carlos III (co-financed by the European Regional Development Fund FEDER “Una manera de hacer Europa”), grant numbers PI13/00364, PI16/00471, PI14/01134 and PI17/00275. A.R.-U. was funded by Instituto de Salud Carlos III predoctoral contract FI17/00031. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain [RD16/0019/0021]. J.L.S.-Q. is a member of the CIBER of Diabetes and Metabolism (CIBERDEM), ISCIII, Spain. M.H.-G. is supported by the Miguel Servet programme, ISCIII, Spain [CPII17/00010]. A.R.-U., N.P., S.B. and J.L.S.-Q. are members of the Quality Research Group 2017-SGR-1149 from Generalitat de Catalunya. A.R.-U., N.P., S.B. and J.L.S.-Q. are members of the Group of Vascular Biology from the Spanish Atherosclerosis Society.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Identifying new blood biomarkers of neuroplasticity associated with rehabilitation outcomes after stroke

  • García Rodríguez, Nicolás
  • García-Gabilondo, Miguel
  • Rodriguez, Susana
  • Tejada Ezquerro, Pedro Ignacio
  • Miranda-Artieda, Zuberoa Maite
  • Ridao, Natalia
  • Buxo Masip, Xavier
  • Perez-Mesquida, Maria Engracia
  • Valor-Blanquer, Júlia
  • Penalba Morenilla, Anna
  • Pérez, Laura Mónica
  • Inzitari, Marco
  • Lamana Vallverdú, Marcel
  • Delgado Martínez, María Pilar
  • Rosell Novel, Anna
Biomarker; Neuroplasticity; Recovery, Biomarcador; Neuroplasticitat; Recuperació, Biomarcador; Neuroplasticidad; Recuperación, Blood biomarkers in stroke patients seek to guide decision-making in clinical practice, but research on those that respond to brain recovery and their relationship with rehabilitation is still limited. Our aim was to explore the value of known neuroplasticity-related molecules, such as endostatin, growth and differentiation factor-10 (GDF-10), urokinase-type plasminogen activator (uPA) and the uPA receptor (uPAR), as blood biomarkers of recovery during poststroke rehabilitation. In an observational, prospective and multicenter study, biomarker levels were assessed after stroke in a cohort of 62 stroke patients with outcome evaluations and blood sampling before starting rehabilitation and during therapy at 1, 3 and 6 months of first visit, and in 43 control subjects. Serum levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) together with a complete battery of sensorimotor and functional tests/scales: modified Rankin Scale (mRS), Barthel Index (BI), Fugl-Meyer Assessment (FMA) for the upper extremity, Functional Ambulation Categories (FAC), Chedoke Arm and Hand Activity Inventory (CAHAI), 10-m walk test and the Medical Research Council (MRC). Statistical mixed linear models were built to investigate its prognostic value. The results revealed that, compared to controls, only endostatin was significantly increased at baseline after stroke (p < 0.01). Interestingly, the highest baseline GDF-10 or uPAR values were related to unfavorable scores during the complete follow-up (p < 0.05 for walking speed or MRC with GDF-10, and for FMA or MRC with uPAR), whereas decreased endostatin or increased GDF-10 biomarker changes at first month of rehabilitation were related to greater sensorimotor and functional improvements during follow-up (p < 0.05 for FMA or MRC with endostatin, and CAHAI or BI with GDF-10). Our results position endostatin, GDF-10 and uPAR as potential blood biomarkers to monitor recovery during rehabilitation after stroke., N.G-R. is doing a doctorate at the Departament de Medicina de la Universitat Autònoma de Barcelona. Research grants from the Instituto de Salud Carlos III with European Regional Development or Next Generation Founds to A.R. or J.B.S. supported this study (PI16/00981, PI19/00186, RD16/0019/0021, RD16/0019/0008, RD21/0006/0007, and RD21/0006/0014), as well as the 2021-SGR-0656 programme from the Generalitat de Catalunya-AGAUR. N.G-R. received a predoctoral fellowship from VHIR, and MG-G. received a research support grant (PERIS, SLT017/20/000197).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Angiogenin in the Neurogenic Subventricular Zone After Stroke

  • Gabriel Salazar, Marina
  • Lei (Santiago), Ting
  • Grayston Morales, Alba
  • Costa Riu, Carme
  • Medina Gutierrez, Esperanza
  • Montaner Villalonga, Joan
  • Rosell Novel, Anna
  • Comabella Lopez, Manuel
Angiogenina; Exercici; Neuroreparació, Angiogenina; Ejercicio; Neuroreparación, Angiogenin; Exercise; Neurorepair, Ischemic stroke is a leading cause of death and disability worldwide with effective acute thrombolytic treatments. However, brain repair mechanisms related to spontaneous or rehabilitation-induced recovery are still under investigation, and little is known about the molecules involved. The present study examines the potential role of angiogenin (ANG), a known regulator of cell function and metabolism linked to neurological disorders, focusing in the neurogenic subventricular zone (SVZ). Angiogenin expression was examined in the mouse SVZ and in SVZ-derived neural stem cells (NSCs), which were exposed to exogenous ANG treatment during neurosphere formation as well as in other neuron-like cells (SH-SY5Y). Additionally, male C57Bl/6 mice underwent a distal permanent occlusion of the middle cerebral artery to study endogenous and exercise-induced expression of SVZ-ANG and neuroblast migration. Our results show that SVZ areas are rich in ANG, primarily expressed in DCX+ neuroblasts but not in nestin+NSCs. In vitro, treatment with ANG increased the number of SVZ-derived NSCs forming neurospheres but could not modify SH-SY5Y neurite differentiation. Finally, physical exercise rapidly increased the amount of endogenous ANG in the ipsilateral SVZ niche after ischemia, where DCX-migrating cells increased as part of the post-stroke neurogenesis process. Our findings position for the first time ANG in the SVZ during post-stroke recovery, which could be linked to neurogenesis., MG-S was supported by a pre-doctoral fellowship from the Vall d'Hebron Research Institute, AR was supported by the Miguel Servet program and AG holds a pre-doctoral fellowship both from Instituto Carlos III (CPII15/00003 and FI17/00073, respectively), and TL was supported by the China Scholarship Council (CSC-201706170048). This research has been funded by grants PI16/00981, PI19/00186, and RD16/0019/0021 (RETICS-INVICTUS PLUS) from the Instituto de Salud Carlos III co-financed by the European Regional Development Funds, and by the Generalitat de Catalunya (2017SGR 1427).